GOSS Gossamer Bio, Inc. Loading...

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
Time Author Thesis Company / ticker Signal Since call Position Source
22:30
Feb 22
seedy19tron
Expects Gossamer Bio to fail
The author expects Gossamer Bio to fail at an upcoming event, in line with what many others expect. They disclose no position or short; this is a bearish expectation.
GOSS Gossamer Bio, Inc. Avoid — —
02:37
Feb 04
u/vikznl
r/biotech_stocks
Phase 3 PROSERA catalyst with strong FC III signal odds
The author argues seralutinib has validated Phase 2 signals in the FC III subgroup and that the Phase 3 PROSERA trial is enriched to replicate that effect. Positive data could trigger re-rating and pharma involvement in PAH, with a 40-45% chance of a franchise-tier result. The main stated risk is a 5-10% true failure risk.
GOSS Gossamer Bio, Inc. Long 1ST — —
19:11
Jan 30
seedy19tron
Bearish GOSS into Q1 catalysts
The author says they are bearish on Gossamer Bio going into its Q1 catalysts. They give no detailed reasoning and disclose no short position.
GOSS Gossamer Bio, Inc. Avoid — —

About GOSS Investor Commentary

Across the available history and selected sources, Buzzberg tracks GOSS (Gossamer Bio, Inc.) across 6 sources: 1 bullish vs 0 bearish calls from 6 authors. Historical directional balance: 11% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 9 total trade ideas tracked. Latest voices: seedy19tron, u/vikznl.